REG - AstraZeneca PLC - AstraZeneca appoints Iskra Reic EVP International

AstraZenecaAnnouncement

04/12/2024 13:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241204:nRSD8090Oa&default-theme=true

RNS Number : 8090O  AstraZeneca PLC  04 December 2024

 

4 December 2024

 

AstraZeneca appoints Iskra Reic as Executive Vice President, International

AstraZeneca today announced the appointment of Iskra Reic as Executive Vice
President (EVP), International with responsibility for overall strategy and
driving sustainable growth across this broad region. This encompasses China,
Asian and Eurasian markets, Middle East & Africa, Latin America, Australia
& New Zealand.

Having joined the Company in 2001, Iskra has held leadership positions across
Central & Eastern Europe, Eurasia, Middle East & Africa. She was
appointed EVP for Europe & Canada in 2017 and joined AstraZeneca's Senior
Executive Team. Most recently, Iskra launched the Company's Vaccines and
Immune Therapies unit, successfully establishing it at the forefront of a new
and exciting era of disease prevention. In this role, she was responsible for
the early and late-stage development of the pipeline and portfolio, including
COVID-19 and RSV vaccines and monoclonal antibodies, strategic partnerships
and acquisitions, medical affairs and commercial operations.

Pascal Soriot, CEO, said: "Iskra is a highly accomplished leader with
extensive international experience across multiple disciplines and a track
record of improving patient access to our innovative and life-changing
medicines. Her experience building partnerships will be invaluable in taking
the fast-growing International region forward."

Iskra Reic, Executive Vice President, International, said: "It is a privilege
to lead this broad, diverse and innovative region as we deliver the next wave
of science and innovative medicines. I look forward to working with our
partners, stakeholders and colleagues to improve the lives of millions of
people around the world with our leading medicines and vaccines."

Iskra succeeds Leon Wang who is on extended leave from the Company while under
investigation in China.

Biography of Iskra Reic

Iskra Reic joined AstraZeneca in 2001 and has since held numerous leadership
positions within the Company, including as Executive Vice-President (EVP) for
Europe & Canada and, since 2021, as EVP, Vaccines & Immune Therapies.
She has also held senior roles across Central & Eastern Europe, Eurasia,
Middle East and Africa. Iskra has served on AstraZeneca's Senior Executive
Team since 2017.

 

As EVP, Vaccines & Immune Therapies, Iskra was responsible for both the
early and late-stage development of the Unit's pipeline and portfolio,
including COVID-19 and RSV vaccines and monoclonal antibodies, strategic
partnerships and acquisitions, medical affairs and commercial operations.

 

Iskra has a PhD and an MBA in Business and Leadership from the IEDC-Bled
School of Management, Slovenia. She also holds a DMD from the Medical
University of Zagreb. She is a member of the Board of Directors of
myTomorrows, a global health technology company, and Steering Committee of the
Partnership for Health System Sustainability and Resilience, a global
collaboration dedicated to improving patient outcomes.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZLFBZLLXFBK